Sugi Predict

Sugi Predict / Targets / NOTCH1

NOTCH1

Neurogenic locus notch homolog protein 1 · P46531 · NOTCH1 on Sugi Atlas →

7,837 patent compounds predicted against NOTCH1, 5,095 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3287597 SCHEMBL3287597 0.67 18/20
SCHEMBL4471840 SCHEMBL4471840 0.75 16/20
SCHEMBL4412662 SCHEMBL4412662 0.59 16/20
SCHEMBL3287510 SCHEMBL3287510 0.73 15/20
SCHEMBL3289302 SCHEMBL3289302 0.73 15/20
SCHEMBL3289672 SCHEMBL3289672 0.73 15/20
SCHEMBL3287399 SCHEMBL3287399 1.00 14/20
SCHEMBL3287605 SCHEMBL3287605 1.00 14/20
SCHEMBL3287889 SCHEMBL3287889 1.00 14/20
SCHEMBL3289687 SCHEMBL3289687 1.00 14/20
SCHEMBL3290276 SCHEMBL3290276 1.00 14/20
SCHEMBL3290519 SCHEMBL3290519 1.00 14/20
SCHEMBL4110243 SCHEMBL4110243 1.00 14/20
SCHEMBL3287198 SCHEMBL3287198 0.83 14/20
SCHEMBL3287317 SCHEMBL3287317 0.83 14/20
SCHEMBL3287486 SCHEMBL3287486 0.83 14/20
SCHEMBL3293655 SCHEMBL3293655 0.83 14/20
SCHEMBL3289038 SCHEMBL3289038 0.82 14/20
SCHEMBL3295109 SCHEMBL3295109 0.79 14/20
SCHEMBL3293678 SCHEMBL3293678 0.71 14/20

Clinical trials — most relevant to NOTCH1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) PHASE3COMPLETED
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis PHASE2COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma PHASE1/PHASE2COMPLETED
A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome; PHASE2COMPLETED
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery PHASE2WITHDRAWN
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer PHASE1/PHASE2COMPLETED
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
NG2 and DLL3 CAR-T Cells Targeting Melanoma PHASE1/PHASE2RECRUITING
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL PHASE2COMPLETED
Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study) PHASE2COMPLETED
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery PHASE1COMPLETED
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors PHASE1RECRUITING
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors PHASE1COMPLETED
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia PHASE1WITHDRAWN
A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor PHASE1COMPLETED
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma PHASE1COMPLETED
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Emerging Role of NOTCH-related Long Non-coding RNA(s) as Biomarkers in Liquid Biopsy From Colorectal Cancer Patients nanCOMPLETED
Does Notch Regulate Glioma Proliferation ? nanCOMPLETED
Prospective Primary Human Lungcancer Organoids to Predict Treatment Response nanCOMPLETED
AusCADASIL: An Australian Cohort of CADASIL nanRECRUITING
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia nanCOMPLETED
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma nanUNKNOWN
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches. nanRECRUITING
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia nanUNKNOWN
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo nanRECRUITING
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome nanCOMPLETED
MR Elastography in Intracranial Lesions: Feasibility & Accuracy nanACTIVE_NOT_RECRUITING
Genetic Variants of Selected Genes in Colo-Rectal Cancer Patients. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NOTCH1 binder may also engage these)

ProteinNameSimilarity
Q01705 — 1.000 Q01705 →
Q07008 — 1.000 Q07008 →
G3I6Z6 — 1.000 G3I6Z6 →
O35516 — 1.000 O35516 →
Q9QW30 — 1.000 Q9QW30 →
NOTCH2 Neurogenic locus notch homolog protein 2 0.997 landscape →
P21783 — 0.996 P21783 →
P46530 — 0.995 P46530 →
Q61982 — 0.994 Q61982 →
A2RUV0 — 0.993 A2RUV0 →
P07207 — 0.991 P07207 →
P78504 — 0.990 P78504 →
Q5ZQU0 — 0.990 Q5ZQU0 →
Q70E20 — 0.988 Q70E20 →
Q9QXX0 — 0.987 Q9QXX0 →
A0A096LNW5 — 0.986 A0A096LNW5 →
Q63722 — 0.985 Q63722 →
Q9R172 — 0.985 Q9R172 →
Q8TER0 — 0.985 Q8TER0 →
P0DPK3 — 0.985 P0DPK3 →
B8JI71 — 0.984 B8JI71 →
Q90Y54 — 0.983 Q90Y54 →
Q90Y57 — 0.981 Q90Y57 →
P97607 — 0.979 P97607 →
Q7Z3S9 — 0.979 Q7Z3S9 →
NOTCH3 Neurogenic locus notch homolog protein 3 0.978 landscape →
O57409 — 0.977 O57409 →
Q95116 — 0.976 Q95116 →
Q61483 — 0.976 Q61483 →
Q9NR61 — 0.976 Q9NR61 →